Home | Clinical Care | Research | Training | Division Activities

Education and Training:

B.A., Chemistry, Northwestern University (1975)

M.D., Vanderbilt University (1979)

Residency in Medicine, Rush Presbyterian-St. Lukes, Chicago, IL (1980-82)

Fellowship in Hematology/Oncology, University of Michigan, Ann Arbor, MI (1984-88)

Research Associate, Howard Hughes Medical Institute, Ann Arbor, MI (1985-88)

Barbara A. Konkle, M.D.
Professor of Medicine
University of Washington School of Medicine

Associate Chief Scientific Officer
Director, Hemostasis, Platelet Immunology and Genomics Laboratory
Bloodworks NW

Photo Dr. Barbara Konkle


Office Address:
Bloodworks NW
Box 359190
921 Terry Avenue
Seattle, WA 98104
Phone:   (206) 689-6191
E-mail:   BarbaraK@BloodworksNW.org

CURRENT CLINICAL INTERESTS

Disorders of hemostasis and thrombosis


CURRENT RESEARCH INTERESTS

Clinical and translational research in hemostasis, thrombosis, transfusion medicine, and sickle cell disease


RESEARCH DESCRIPTION

Clinical Studies/Trials in Hemostasis, Thrombosis and Sickle Cell Disease:

Dr. Konkle has several active funded studies focusing on the clinical impact of hemostasis and sickle cell disease. These include: 1) A nationwide project to genotype patients with hemophilia, establish a research repository and analyze data including as part of the NHLBI Transomics in Precision Medicine (TOPMed) project, 2) Development of better assays for von Willebrand disease (HHS, NIH), 3) A cross sectional analysis of cardiovascular disease and complications of anticoagulant and antithrombotic therapy in men with moderate and severe hemophilia (CDC), 4) A study of N-acetylcysteine in patients with sickle cell disease as adjunctive treatment in pain crises (NHLBI R34), and 5) Clinical trials of new treatments for bleeding disorders.


REPRESENTATIVE PUBLICATIONS

Rodger M, Phillips P, Kahn SR, James AH, Konkle BA. Low-molecular-weight heparin to prevent postpartum venous thromboembolism: A pilot randomized placebo-controlled trial. Thromb Haemost 2015;113:212-216.

James AH, Konkle BA, Kouides P, Ragni MV, Thames B, Gupta S, Sood S, Fletcher SK, Philipp CS. Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for phrophylaxis. Haemophilia. 2015;21:81-87.

Konkle BA, Stasyshyn O, Chowdary P, Bevan DH, Mant T, Shima M, Engl W, Dyck-Jones J, Fuerlinger M, Patrone L, Ewenstein B, Abbuehl B. Pegylated, full-length recombinant factor VIII for phrophylactic and on-demand treatment of severe hemophilia A. Blood 2015; 126:1078-1085. PMCID: PMC4551361.

Recht M, Konkle BA, Pipe S, Neufeld EJ, Jackson S, Rockwood K. Recognizing the need for personalization of haemophilia patient-reported outcomes in the prophylaxis era. Accepted for publication in Haemophilia.

Kuter DJ, Konkle BA, Gerstenberger E, Uhl L, Hamza TH, Assman SF, Kiss JE, Kaufman RM, Key NS, Sachais B, Hess JR, Ness P, McCrae KR, Leissinger C, Strauss RG, McFarland J, Neufeld E, Bussel JB, Ortel TL. Clinical outcomes in patients with heparin-induced thrombocytopenia. Submitted for publication.

Sood SL, James AH, Ragni MV, Shapiro AD, Witmer C, Vega R, Bolgiano D, Konkle BA. A Prospective Study of von Willebrand Factor Levels and Bleeding in Pregnant Women with Type 1 von Willebrand Disease. Accepted for publication in Haemophilia. 2016.

Johnsen JM, Fletcher SN, Huston H, Roberge S, Martin BK, Kircher M, Josephson NC, Shendure J, Ruuska S, Koerper MA, Meltzer L, Pierce GF, Aschman DJ, Konkle BA. Novel Approach to and Results of Genetic Analysis of 3000 Hemophilia Patients Enrolled in the My Life, Our Future Initiative. Submitted for publication.